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Abstract
Background Vitamin D deficiency may accelerate the risk of type 2 diabetes mellitus. The association of vitamin D with
hyperglycemia may be influenced by lifestyle.
Objective To evaluate the relationship between vitamin D status and hyperglycemia among the workers’ population.
Methods This was a medical records review of 7054 Iranian factory workers participating in an annual health check-up for
employees. Of those, potential participants were included in this analysis if data for serum 25-hydroxyvitamin D [25(OH) D]
levels were also available.
Results Data of 429 male participants were used for this analysis. Of those, 61.07% had serum 25(OH)D concentrations lower
than the sufficient level [≥20 ng/ml]. Hyperglycemic participants had significantly lower 25(OH)D than those with normal fasting
blood glucose (FBG). Regression analyses highlighted serum 25(OH)D as a significant determinant of hyperglycemia [OR:
0.943(0.901, 988); p = 0.01]. The association between 25(OH)D and FBG remained significant after adjustment for potential
confounders (p = 0.008). Using the ROC analysis, the serum 25(OH)D value of 14.7 ng/ml was the optimal cut-off point to
predict hyperglycemia in this population (sensitivity: 63.6%, specificity: 62.3%, p = 0.01).
Conclusion Our results revealed a considerable proportion of participants with serum 25(OH)D below the optimal level as well as
a significant inverse association between vitamin D status and hyperglycemia among the factory workers. These findings
highlight the importance of including the evaluation of vitamin D status as a part of annual health examinations for employees,
and may help health policy- makers prevent or delay type 2 diabetes mellitus among the workers’ population.
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Introduction
Diabetes has reached epidemic proportions globally, affecting
over 422 million people in the world [1]. Existing evidence
shows that not only diabetes mellitus, even non-diabetic de-
grees of hyperglycemia are directly linked to the accelerated
risks of morbidity and mortality [2]. Beside health problems,
diabetes also imposes a substantial economic burden on the
society through direct medical costs as well as indirect costs
resulting from productivity loss, which will be increasingly
significant in the working-age population [3].
Vitamin D is a fat-soluble vitamin that plays a crucial role
in many physiological functions, including calcium/
phosphorus homeostasis, bone metabolism, immune system,
cell differentiation and replication as well as glucose hemosta-
sis [4]. Usually, 80–90% of vitamin D in the body is
synthetized in the skin upon sunlight exposure and the remain-
der is obtained through diet. In spite of these dual sources of
attainment, vitamin D deficiency (as judged from serum 25-
hydroxyvitamin D [25(OH)D] levels) is still a global health
concern, estimated to affect at least 1 billion people worldwide
[5]. Epidemiological studies show that even with its abundant
sunshine, Middle-East region has some of the highest rates of
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vitamin D deficiency in the world [6]. In Iran, surveys from
different parts of the country have reported the suboptimal
levels of vitamin D in over 70% of the general population [7].
Despite the lack of consensus on vitamin D level required
for the optimal health, a serum 25(OH)D concentration >
30 ng/ml is generally considered as sufficient, and the values
of 21–29 ng/ml and ≤ 20 ng/ml as vitamin D insufficiency and
deficiency, respectively [8]. Cumulative evidence indicates
that vitamin D deficiency may accelerate the development of
some chronic diseases, including diabetes [9]. On the other
hand, an optimal vitamin D status has been found to be asso-
ciated with a reduced risk [10]. The exact mechanism linking
vitamin D status to hyperglycemia remains somewhat unclear;
however, it is proposed to be in part due to a reduced activity
of pancreatic beta cells leading to a decrease in insulin secre-
tion [11].
As a result of confirming association between vitamin D
status and the occurrence of diabetes in several studies, atten-
tions are now attracted toward the possibility of using serum
25(OH)D levels as a predictive factor in hyperglycemia [12,
13]. Moreover, many recent studies have been focused on
defining the threshold for a sufficient 25(OH)D level in terms
of various measures of glucose and insulin metabolism
[14–16]. However, to the best of our knowledge, there has
been no study reporting a cutoff value for vitamin D deficien-
cy based on the fasting blood glucose levels. In addition, it
was demonstrated that vitamin D predictive power can be
greatly influenced by some underlying factors, including life-
style (e.g. physical activity levels) [17]. Nevertheless, there
have been very limited published literatures investigating the
association of vitamin D status with hyperglycemia in the
factory workers’ populations who generally have high physi-
cal activity. Given the key role of workers in societies, the
present study was designed to investigate: 1) the relationship
between serum vitamin D levels and hyperglycemia in a sam-
ple of male workers, and 2) the optimal cut-off value for vita-
min D deficiency based on the fasting blood glucose levels.
Material and methods
This was a medical record review study conducted in a large
auto manufacturer (SAIPA group) in Karaj, Iran. Karaj is a
major industrial city in northern-central Iran (20 km west of
Tehran), with latitude of 35°50′ N, longitude of 51°00′ E and
an average of 2947 h of sunshine per year. Data were collected
on 7054 male employees who had participated in an annual
health check-up between August 2014 and February 2015. Of
these, potential participants were included in this analysis if
data for serum 25(OH)D concentrations were also available
(n = 429).
Clinical and biomedical data were collected from each par-
ticipant by trained staffs at out-patient clinic, Baharloo
Hospital in Tehran, Iran. Weight and height were measured
with participants dressed in light clothing, without shoes using
a Rasa scale with stadiometer. Body mass index (BMI) was
calculated as weight in kilogram divided by height in meters
squared. Participants’ blood pressures were taken in the sitting
position using an aneroid sphygmomanometer (ABN™,
Premium) with a standard cuff (normal BP: SBP/DBP < 140/
90 mmHg and no anti-hypertensive medication; high BP:
SBP/DBP ≥ 140/90 mmHg or on anti-hypertensive medica-
tions). Fasting blood samples were collected via venipuncture
into serum tubes, and were subsequently sent to the hospital
laboratory (Baharloo hospital, Tehran, Iran) to be analyzed for
fasting blood glucose (FBG), triglyceride, cholesterol, HDL-
cholesterol, LDL-cholesterol, SGOT, and SGPT.
All participants were also asked to complete a question-
naire starting with a set of general questions, followed by
asking about their medical history and smoking status (three
categories: non-smoker, current smoker and ex-smoker).
Blood glucose levels were determined with enzymatic col-
orimetric method (normal range: FBG <100 mg/dl).
Enzymatic assays were also used to determine the levels of
serum triglyceride (normal range: TG <200 mg/dl), total cho-
lesterol (normal range: cholesterol<200 mg/dl), HDL-
cholesterol (normal range: HDL ≥ 35 mg/dl) and LDL-
cholesterol (normal range: LDL ≤ 130 mg/dl). UV kinetic
methods were used to determine SGOT (normal range:
SGOT <37 IU/L) and SGPT (normal range: SGPT<41 IU/L)
levels in serum samples. All analyses were performed
using Pars Azmun diagnostic kits (Pars Azmun Co.,
Tehran, Iran) with a between- and within-run coefficient
of variation <6.2%.
This study was approved by the ethics committee of Iran
University of Medical Sciences (approval number:
IR.IUMS.REC.1396. 32,734). As this study involved the re-
view of existing medical records, the committee waived the
requirement to obtain informed consent from the participants.
Statistical analysis
Statistical analyses were carried out using IBM SPSS
Statistics for Windows (Version 20.0 IBM Corp. Released
2011. Armonk, NY: IBM Corp). Descriptive statistics for var-
iables of interest were obtained and normality was assessed
using the Kolmogorov-Smirnov test. Unless otherwise stated,
results were presented as the mean value ± standard deviation,
or as median with inter quartile range for skewed data.
Comparison of demographic and clinical characteristics be-
tween groups was undertaken using χ2 test, independent sam-
ple t-test or Mann-Whitney U test as appropriate (Table 1).
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In the present study, participants were classified as
normoglycemic (FBG < 100 mg/dl) or hyperglycemic
(FBG ≥ 100 mg/dl) based on the American Diabetes
Association (ADA) cut-offs for normal FBG [18]. Also, they
were categorized as normal, overweight and obese according
to the standard cutoffs (BMI < 25 kg/m2, 25 ≤BMI < 30 and
BMI ≥ 30, respectively). Physical activity levels were catego-
rized as low: < 150 min/week of moderate-intensity activity,
moderate: 150–300 min/week of moderate-intensity activity
or 75–150 min/week of vigorous-intensity physical activity,
high: > 300 min/week of moderate-intensity activity or >
150 min/week of vigorous-intensity physical activity.
The associations between serum 25(OH)D and having
higher fasting blood glucose were examined using multiple
logistic regression analyses, and the results were presented
as odds ratio (OR) and 95% CI (Table 2). Serum 25(OH)D
was entered into the regression analysis as: 1) a continuous
variable (ng/ml) and 2) a categorical variable based on
Table 1 Demographic and clinical characteristics of participants by fasting blood glucose (FBG)
Normoglycemic group (FBG < 100 mg/dl)
n = 396 (92.3%)
Hyperglycemic group (FBG ≥ 100 mg/dl)
n = 33 (7.7%)
P value
Age (y) 37 (35–40) 38 (36–44) 0.30
BMI (kg/m2) 26.8 (25.1–28.7) 28.4 (24.8–29.9) 0.22
Waist circumference (cm) 93.5 (89.0–99.0) 97.0 (90.0–101.5) 0.23
Triglyceride (mg/dl) 150.0 (105.0–205.0) 179.0 (111.5–268.5) 0.17
Cholesterol (mg/dl) 189.0(160.3–209.0) 186.0 (162.0–225.5) 0.48
Systolic blood pressure (mmHg) 110.0 (105.0–120.0) 120.0 (110.0–120.0) 0.23
Diastolic blood pressure (mmHg) 80.0 (70.0–80.0) 80.0(70.0–80.0) 0.42
SGOT (IU/L)* 23.0 (19.0–28.0) 21.5 (19.8–26.25) 0.64
SGPT (IU/L)* 31.5 (23.0–41.0) 32.0 (26.7–41.0) 0.52
Serum 25(OH)D (ng/ml) 17.0 (12.0–25.2) 13.3 (7.8–20.9) 0.01
25(OH)D quartiles 0.24
1st quartile (≤11.70 ng/ml) 96 (88.9%) 12 (11.1%)
2nd quartile (11.80–16.60 ng/ml) 100 (91.7%) 9 (8.3%)
3rd quartile (16.70–24.85 ng/ml) 97 (92.4%) 8 (7.6%)
4th quartile (>24.85 ng/ml) 103 (96.3%) 4 (3.7%)
25(OH)D status1 0.20
Deficient [25(OH)D < 12 ng/ml] 94 (88.7%) 12 (11.3%)
Insufficient [12 ≤ 25(OH)D < 20 ng/ml] 144 (92.3%) 12 (7.7%)
Optimal (≥20 ng/ml) 158 (94.6%) 9 (5.4%)
25(OH)D status2 0.03
Deficient [25(OH)D ≤ 20 ng/ml] 243 (90.7%) 25 (9.3%)
Insufficient [21 ≤ 25(O)HD ≤ 29 ng/ml] 85 (91.4%) 8 (8.6%)
Optimal (≥30 ng/ml) 68 (100%) 0 (0%)
Smoking status 0.10
Current smoker3 72 (91.1%) 7 (8.9%)
Ex-smoker4 5 (71.4%) 2 (28.6%)
Non-smoker 319 (93.0%) 24 (7.0%)
Physical activity level 0.52
Low 56 (14.1%) 4 (12.1%)
Moderate 116 (29.3%) 7 (21.2%)
High 224 (56.6%) 22 (66.7%)
* In a sub group of study population (n = 330), including 304 individuals with FBG <100, and 26 hyperglycemic subjects; 1 categorized based on US
Institute of Medicine (IOM) recommendation; 2 categorized based on Endocrine Society recommendation; 3 Current smoker, an adult who has smoked
at least 100 cigarettes in his/her lifetime and currently smokes cigarettes; 4 Ex-smoker, an individual who was previous current smoker, but has been
smoke-free for at least 28 days
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25(OH)D quartiles, with lowest category as the reference. P-
values for trend were calculated by the category median
values [19].
The best cut-off value of serum 25(OH)D to predict hyper-
glycemia was determined using receiver operating character-
istic (ROC) analysis (Fig. 1). All tests were two-tailed and a
p < 0.05 was considered as statistically significant.
Results
Participants included in this analysis were 429 Iranian men
aged between 28 to 68 years, with a median BMI of
26.81 kg/m2. Of those, 92.3% had a normal FBG (<100 mg/
dl) and 7.7% had a FBG level higher than the normal range (≥
100 mg/dl). Statistics describing the demographic and clinical
Table 2 The results of logistic regression models evaluating the association between serum 25(OH)D and high FBG levels
Model 1 Model 2 Model 3
Crude OR (95% CI) AOR (95% CI) AOR (95% CI)
25(OH)D continuous (ng/ml) 0.943 (0.901, 988) 0.942 (0.900, 0.986) 0.918 (0.861,0.978)
p value 0.013 0.011 0.008
Model 1 Model 2 Model 3
25(OH)D quartiles Crude OR (95% CI) AOR (95% CI) AOR (95% CI)
1st Q (8.60 ng/ml)§ 1.0 1.0 1.0
2nd Q (14.30 ng/ml)§ 0.720 (0.290,1.786) 0.777 (0.305,1.983) 0.803 (0.273, 2.366)
3rd Q (29.97 ng/ml)§ 0.660 (0.258,1.686) 0.648 (0.245,1.714) 0.230(0.050,1.060)
4th Q (31.00 ng/ml)§ 0.311(0.097,0.996)* 0.296 (0.089,0.987)* 0.284 (0.072, 1.121)
p for trend 0.088 0.078 0.015
Model 1: With no adjustment; Model 2: Adjusted for age, BMI, examination season, physical activity, smoking status; Model 3: Model 2 plus WC,
cholesterol, triglyceride, systolic blood pressure, diastolic blood pressure, liver function test (SGOT, SGPT); *, significant in comparison to the reference
group (1st Q) at 5% significance level;§, median of the quartile group; Values in bold denote statistical significance at the p < 0.05 level.
Fig. 1 Receiving operating
characteristic (ROC) curve and
the best cut-off of serum
25(OH)D associated with
hyperglycemia
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characteristics of normal and hyperglycemic groups are pre-
sented in Table 1. While, the two groups of participants were
comparable in terms of different characteristics including age,
BMI, waist circumference (WC), systolic and diastolic blood
pressure, serum triglyceride, cholesterol, SGOT, SGPT,
smoking status and physical activity levels; the hyperglycemic
group had a significantly lower serum 25(OH)D than the
group with normal FBG [median 13.3 ng/ml, IQR 7.8–20.9
vs. 17.0 ng/ml, 12.0–25.2; p = 0.01]. Hyperglycemia was rec-
ognized in 9.3% (25/268) of participants who were vitamin D
deficient (serum 25(OH)D ≤ 20 ng/ml, n = 268) and 8.6%
(8/93) of those being vitamin D insufficient [21 ≤
25(OH)D ≤ 29 ng/ml, n = 93], according to the Endocrine
Society guideline [8]. However, all participants with a serum
25(OH)D levels of 30 ng/ml or greater (n = 68) had a FBG at
the normal range [Table 1].
Using the IOM classification for vitamin D status [20],
vitamin D deficiency [serum 25(OH)D < 12 ng/ml (30 nmol/
l)] was more prevalent among participants with hyperglyce-
mia than those having normal FBG [36.4% (12/33) vs. 23.7%
(94/396)]. In addition, 72.7% (24/33) of participants with hy-
perglycemia had a serum 25(OH)D lower than the optimal
level [< 20 ng/ml (50 nmol/l)] compared to 60.1% (238/396)
in the normoglycemic group.
There was no significant difference between serum
25(OH)D levels measured in normal, overweight, and obese
participants, in either normoglycemic [normal: 16.6 (12.4–
23.0) ng/ml, overweight: 17.4 (11.6–26.8) ng/ml, obese:
16.0 (12.0–23.6) ng/ml; p = 0.70] or hyperglycemic groups
[normal: 13.0 (7.1–26.7) ng/ml, overweight:13.2 (8.8–18.5)
ng/ml, obese:19.3 (7.0–23.0) ng/ml; p = 0.69). There was also
no significant difference between serum 25(OH)D measured
in participants with and without central obesity [16.85 (11.4–
24.27) vs. 16.26 (12.30–25.87) ng/ml, p = 0.71) categorized in
terms of waist circumference (WC ≥ 94 cm or WC< 94 cm,
respectively). Furthermore, no significant association was
found between serum levels of 25(OH)D and age, BMI,
WC, lipid profile, blood pressure or liver function tests (all
p values >0.05).
Logistic regression analyses highlighted serum 25(OH)D
as a significant determinant of having a high FBG (Table 2).
When the serum 25(OH)D was entered into the regression
model as a continuous variable, every unit increase in serum
25(OH)D significantly reduced the odds of hyperglycemia by
5.7% (OR: 0.943 (0.901, 988); p = 0.01) in model 1. The
association between serum 25(OH)D and FBG remained sig-
nificant after adjustment for age, BMI, season, smoking status
and physical activity in model 2 (AOR 0.942 (0.900, 0.986);
p = 0.01) and additional adjustment for WC, systolic and dia-
stolic blood pressures, lipid profile and liver function test in
model 3 (AOR 0.918 (0.861,0.978); p = 0.008). Analysis by
quartiles of serum 25(OH)D showed that the people in the
highest quartile [serum 25(OH)D > 24.85 ng/ml] had a
significantly reduced odds of having hyperglycemia com-
pared to those in the lowest quartile [serum 25(OH)D ≤
11.70 ng/ml, p < 0.05 in models 1 & 2], although this associ-
ation attenuated after final adjustment for CVD risk factors in
model 3 (p = 0.07 for Q4 vs. Q1; p = 0.01 for trend).
Using the ROC analysis for the entire group, the serum
25(OH)D value of 14.7 ng/ml was the best cut-off point to
predict hyperglycemia in the population (sensitivity: 63.6%,
specificity: 62.3%, Yoden’s index: 0.259, p = 0.01), (Fig. 1).
Considering this cut-off, 39.4% of participants (37.4% in
normoglycemic group & 63.6% in hyperglycemic group)
were vitamin D deficient.
Discussion
In the present study the lower levels of serum 25(OH)D were
significantly associated with the higher odds of having hyper-
glycemia in a sample of Iranian male workers. This associa-
tion was independent of potential confounders including age,
BMI, WC, season, smoking status, physical activity and bio-
medical factors. These findings are in agreement with several
observations revealing an inverse relationship between vita-
min D status and disturbances in glucose metabolism [12,
21–23]. For instance, the cohort study by Forouhi et al. [12]
provides strong evidence showing that the baseline measures
of serum 25(OH)D are inversely related to 10-year risk of
hyperglycemia. In another prospective study with an average
follow-up of 2.7 years, after adjusting for confounders, higher
plasma 25(OH)D was significantly associated with a reduced
risk of incident diabetes in patients with pre-diabetes [22].
Similarly, in a recent cross-sectional population-based study,
Pannu et al. [21] found that, independent of metabolic syn-
drome components, individuals in the high tertile of 25(OH)D
had a 39% reduced odds of hyperglycemia compared to those
in the low 25(OH)D tertile. However, our results do not sup-
port the study conducted by Haslacher et al. [17] suggesting
that low levels of serum vitamin D may not predict hypergly-
cemia in individuals with intense physical activity.
Despite robust evidence in observational studies, clinical
trials has somewhat failed to favour the notion that vitamin D
supplementation can help prevent and/or control diabetes
mellitus in people at high risk. While a meta-analysis showed
that vitamin D supplementation may reduce fasting plasma
glucose and HbA1C in pre-diabetes [24], it had no significant
effect on glucose and insulin metabolism in patients with type
2 diabetes or those who were overweight and obese in two
other systematic reviews [25, 26]. This discrepancy could hy-
pothetically be due to differences in the population under
study, small sample sizes or inappropriate study design [27,
28]. In fact, the majority of intervention studies on this topic
had fewer than 100 participates [29] and administrated
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vitamin D for a relatively short period [30] or with an inade-
quate dose [31].
Several potential mechanisms have been proposed to ex-
plain the association of vitamin D deficiency with hypergly-
cemia and insulin resistance [11]. The expression of vitamin D
receptors in pancreatic islets highlights the possible role of
vitamin D in the β-cell secretory function [32]. Vitamin D is
also involved in the regulation of intracellular calcium hemo-
stasis, which in turn is crucial for the action of insulin on
various peripheral tissues such as skeletal muscle and adipose
tissue [33, 34]. Another possible mechanism linking vitamin
D and insulin sensitivity involves the vitamin D-parathyroid
(PTH) axis [35]. Finally, adequate levels of 25(OH)D are re-
quired to modulate inflammatory pathways in the body [36].
Hypovitaminosis D may accordingly promote insulin resis-
tance and the subsequent risk of diabetes mellitus through
amplifying inflammatory responses [37].
Notwithstanding a large number of studies on vitamin D,
there is still no general consensus on the optimal threshold
reflecting a sufficient circulating 25(OH)D concentration,
and it may vary in terms of outcomes and populations. Two
main guidelines for interpreting 25(OH)D levels have been
established primarily on the basis of the studies on bone
health. According to the Endocrine Society, vitamin D defi-
ciency and insufficiency are defined by serum 25(OH)D levels
<20 ng/ml and 21–29 ng/ml respectively, and a serum
25(OH)D level ≥ 30 ng/ml is considered as sufficient [8].
However, the Institute of Medicine (IOM) classifies
25(OH)D concentration of <12 ng/ml as deficient and advo-
cates a serum 25(OH)D ≥ 20 ng/ml as sufficient [20].
Furthermore, due to well-established links between vitamin
D and the pathogenesis of other diseases including CVD, the
guidelines for interpreting 25(OH)D levels need to consider
the endpoints beyond the skeletal system as well.
Accordingly, many recent studies have been focused on de-
fining the threshold for a sufficient 25(OH)D level in terms of
various non-bone related outcomes, including hypertension,
body mass index, cardiovascular events as well as different
measures of glucose and insulin metabolism (i.e. indices of
insulin sensitivity and resistance, fasting and 2-h insulin
levels, and 2-h plasma glucose concentration) [14–16]. To
the best of our knowledge, this study is the first reporting a
cutoff value for vitamin D deficiency based on the fasting
blood glucose levels. In the present study, a serum 25(OH)D
level of about 15 ng/ml was determined as the optimal cut-off
point to predict hyperglycemia in the target population.
Though this point was lower than the threshold of ~26 ng/ml
suggested to be required for normal glucose metabolism [15],
it was quite similar to the cut-off determined by Ashraf et al.
[14] on the basis of an insulin sensitivity index. Indeed, our
results support recent evidence revealing that the current cut-
off of 20 ng/ml may be higher than required in healthy people
who are not at risk for vitamin D deficiency [8, 38, 39].
In this study, serum levels of 25(OH)D were not correlated
with BMI. There was also no significant difference between
serum 25OH levels measured in normal, overweight and
obese participants categorized on the basis of BMI. These
findings are in line with some previous studies conducted on
Iranian population revealing that despite a significant inverse
association with fat mass, circulating 25(OH)D levels were
not associated with BMI [40]. The strong correlation of vita-
min D status with adiposity has been proven in several studies
[41, 42]; however, the accuracy of BMI as a surrogate indica-
tor of adiposity is still debated [43]. Besides, in studies using
both body fat percentage derived from DXA, and BMI to
predict 25(OH)D levels, only body fat percentage remained
as an independent determinant in the final model [44]. In the
present study, serum 25(OH)D levels also did not exhibit any
correlation with waist circumference. Studies examining the
link between vitamin D status and waist circumference have
reported controversial results [40, 45, 46]. The discrepancy
between these findings may be in part due to the fact that
circulating levels of 25(OH)D are mostly correlated to visceral
adipose tissue [47]; however, waist circumference has gener-
ally a stronger association with subcutaneous adipose tissue
than with visceral fat [48]. As a result, it may misclassify
individuals in respect of visceral adiposity and its related met-
abolic risks [49]. In this context, it should be also noted that
the population included in our analysis was a sample of male
factory workers, the majority with a high physical activity
level. Accordingly, due to previous studies examining the as-
sociation of physical activity with the body composition [50],
the BMI and WC determined for this population could be
assumed to reflect their lean-tissue mass rather than the fat
mass.
The present study should be interpreted within the context
of its limitations. First, the cross-sectional nature of study
design limits the possibility of deriving causal relationships.
Moreover, circulating 25(OH)D levels may vary according to
polymorphic variations in several genes involved in vitamin D
metabolism and signaling pathways [51]. Another limitation
is the lack of data on the family history of diabetes which can
be a potential confounder. The annual health checkup did not
also include the employees’ dietary information, although due
to consumption of meals at the factory restaurant served ac-
cording to a certain meal plan, the participants’ dietary habits
could be assumed not to differ, considerably. Lastly, consider-
ing a specific group (factory workers) may limit the general-
izability of our results to the entire population.
In conclusion, our results reveal a significant inverse asso-
ciation between vitamin D status and hyperglycemia in the
factory workers. A serum 25(OH)D level of 14.7 ng/ml was
suggested as an optimal cut-off point to predict hyperglycemia
in this population. These findings along with the considerable
proportion of participants with serum 25(OH)D levels below
this threshold highlight the importance of evaluating vitamin
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D status as a part of annual health checkup for employees to
diagnose individuals with vitamin D deficiency/insufficiency.
Subsequent vitamin D therapy may help prevent or delay type
2 diabetes mellitus in this group of workers.
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